dc.contributor.author | Russell, NS | |
dc.contributor.author | Krul, IM | |
dc.contributor.author | van Eggermond, AM | |
dc.contributor.author | Aleman, BMP | |
dc.contributor.author | Cooke, R | |
dc.contributor.author | Kuiper, S | |
dc.contributor.author | Allen, SD | |
dc.contributor.author | Wallis, MG | |
dc.contributor.author | Llanas, D | |
dc.contributor.author | Diallo, I | |
dc.contributor.author | de Vathaire, F | |
dc.contributor.author | Smith, SA | |
dc.contributor.author | Hauptmann, M | |
dc.contributor.author | Broeks, A | |
dc.contributor.author | Swerdlow, AJ | |
dc.contributor.author | Van Leeuwen, FE | |
dc.date.accessioned | 2018-04-10T08:15:33Z | |
dc.date.issued | 2017-12-01 | |
dc.identifier.citation | Clinical and translational radiation oncology, 2017, 7 pp. 20 - 27 | |
dc.identifier.issn | 2405-6308 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1634 | |
dc.identifier.eissn | 2405-6308 | |
dc.identifier.doi | 10.1016/j.ctro.2017.09.004 | |
dc.description.abstract | BACKGROUND: An increased risk of breast cancer following radiotherapy for Hodgkin lymphoma (HL) has now been robustly established. In order to estimate the dose-response relationship more accurately, and to aid clinical decision making, a retrospective estimation of the radiation dose delivered to the site of the subsequent breast cancer is required. METHODS: For 174 Dutch and 170 UK female patients with breast cancer following HL treatment, the 3-dimensional position of the breast cancer in the affected breast was determined and transferred onto a CT-based anthropomorphic phantom. Using a radiotherapy treatment planning system the dose distribution on the CT-based phantom was calculated for the 46 different radiation treatment field set-ups used in the study population. The estimated dose at the centre of the breast cancer, and a margin to reflect dose uncertainty were determined on the basis of the location of the tumour and the isodose lines from the treatment planning. We assessed inter-observer variation and for 47 patients we compared the results with a previously applied dosimetry method. RESULTS: The estimated median point dose at the centre of the breast cancer location was 29.75 Gy (IQR 5.8-37.2), or about 75% of the prescribed radiotherapy dose. The median dose uncertainty range was 5.97 Gy. We observed an excellent inter-observer variation (ICC 0.89 (95% CI: 0.74-0.95)). The absolute agreement intra-class correlation coefficient (ICC) for inter-method variation was 0.59 (95% CI: 0.37-0.75), indicating (nearly) good agreement. There were no systematic differences in the dose estimates between observers or methods. CONCLUSION: Estimates of the dose at the point of a subsequent breast cancer show good correlation between methods, but the retrospective nature of the estimates means that there is always some uncertainty to be accounted for. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 20 - 27 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER IRELAND LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-09-16 | |
rioxxterms.versionofrecord | 10.1016/j.ctro.2017.09.004 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc-nd/4.0 | |
rioxxterms.licenseref.startdate | 2017-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Clinical and translational radiation oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology | |
pubs.publication-status | Published | |
pubs.volume | 7 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Aetiological Epidemiology | |
dc.contributor.icrauthor | Swerdlow, Anthony | |